{"id":38761,"date":"2025-08-07T12:13:39","date_gmt":"2025-08-07T04:13:39","guid":{"rendered":"https:\/\/flcube.com\/?p=38761"},"modified":"2025-08-07T12:13:40","modified_gmt":"2025-08-07T04:13:40","slug":"beone-medicines-reports-42-revenue-growth-in-q2-2025-driven-by-brukinsa-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38761","title":{"rendered":"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales"},"content":{"rendered":"\n<p>BeOne Medicines Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.<\/p>\n\n\n\n<p><strong>Product Revenue Growth<\/strong><br>In Q2 2025, the company&#8217;s product revenue was $1.3 billion, compared to $921 million in the same period last year. The increase was mainly attributed to the growth of Brukinsa sales. The United States remains the largest market, with product revenue reaching $685 million, up from $479 million in the previous year&#8217;s quarter. Sales of products licensed from Amgen and Tislelizumab also contributed to the revenue growth.<\/p>\n\n\n\n<p><strong>Half-Year Performance<\/strong><br>For the first half of 2025, the company&#8217;s revenue was 17.518 billion yuan (RMB), a 46% year-on-year increase. Product revenue was 17.360 billion yuan, up 45.8%. Global sales of Brukinsa totaled 12.527 billion yuan, an increase of 56.2%. U.S. sales were 8.958 billion yuan, up 51.7%, while European sales reached 1.918 billion yuan, up 81.4%. Sales in China were 1.192 billion yuan, up 36.5%.<\/p>\n\n\n\n<p><strong>Tislelizumab Performance<\/strong><br>Sales of Tislelizumab totaled 2.643 billion yuan in the first half of 2025, an increase of 20.6%. The growth was primarily due to new patient demand from the inclusion of newly approved indications in China&#8217;s national medical insurance system and an increase in the number of hospitals carrying the drug. Tislelizumab has secured a leading market share in the PD-1 market in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BeOne_Q2_2025_Earnings_Deck_FINAL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BeOne_Q2_2025_Earnings_Deck_FINAL.\"><\/object><a id=\"wp-block-file--media-f1349726-d886-4901-9ad1-49d4cc39ee26\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BeOne_Q2_2025_Earnings_Deck_FINAL.pdf\">BeOne_Q2_2025_Earnings_Deck_FINAL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BeOne_Q2_2025_Earnings_Deck_FINAL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f1349726-d886-4901-9ad1-49d4cc39ee26\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/Q2_2025_Earnings_Release_FINAL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q2_2025_Earnings_Release_FINAL.\"><\/object><a id=\"wp-block-file--media-d54706b0-749e-4b9c-b9be-74d008bf163d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/Q2_2025_Earnings_Release_FINAL.pdf\">Q2_2025_Earnings_Release_FINAL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/Q2_2025_Earnings_Release_FINAL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d54706b0-749e-4b9c-b9be-74d008bf163d\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BeOne_Q2_2025_Clinical_Trials_Appendix_FINAL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BeOne_Q2_2025_Clinical_Trials_Appendix_FINAL.\"><\/object><a id=\"wp-block-file--media-98c0a2b3-35ca-4f41-963f-1cdd8dbc4362\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BeOne_Q2_2025_Clinical_Trials_Appendix_FINAL.pdf\">BeOne_Q2_2025_Clinical_Trials_Appendix_FINAL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/BeOne_Q2_2025_Clinical_Trials_Appendix_FINAL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-98c0a2b3-35ca-4f41-963f-1cdd8dbc4362\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38762,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[185,2092,27,847,3046,848],"class_list":["post-38761","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-beigene","tag-beone-medicines","tag-finanical-reports","tag-hkg-6160","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38761\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38761\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T04:13:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T04:13:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales\",\"datePublished\":\"2025-08-07T04:13:39+00:00\",\"dateModified\":\"2025-08-07T04:13:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0705.webp\",\"keywords\":[\"BeiGene\",\"BeOne Medicines\",\"Finanical Reports\",\"HKG: 6160\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38761#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38761\",\"name\":\"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0705.webp\",\"datePublished\":\"2025-08-07T04:13:39+00:00\",\"dateModified\":\"2025-08-07T04:13:40+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38761\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0705.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38761#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38761","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.","og_url":"https:\/\/flcube.com\/?p=38761","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-07T04:13:39+00:00","article_modified_time":"2025-08-07T04:13:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38761#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38761"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales","datePublished":"2025-08-07T04:13:39+00:00","dateModified":"2025-08-07T04:13:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38761"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38761#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0705.webp","keywords":["BeiGene","BeOne Medicines","Finanical Reports","HKG: 6160","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38761#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38761","url":"https:\/\/flcube.com\/?p=38761","name":"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38761#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38761#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0705.webp","datePublished":"2025-08-07T04:13:39+00:00","dateModified":"2025-08-07T04:13:40+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business progress for the second quarter of 2025 on August 6, 2025. The company reported total revenue of $1.3 billion, marking a 42% year-on-year increase. This growth was primarily driven by the sales of Brukinsa (zanubrutinib) in the United States and Europe, with global Brukinsa revenue reaching $950 million, up 49% year-on-year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38761#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38761"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38761#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0705.webp","width":1080,"height":608,"caption":"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38761#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0705.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38761"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38761\/revisions"}],"predecessor-version":[{"id":38766,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38761\/revisions\/38766"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38762"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}